Year-end Sale % OFF 
Abstract
Significant survival benefit is seen with pembrolizumab monotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer and palbociclib for previously untreated, hormone receptor-positive, HER-2 negative, locally advanced, or metastatic breast cancer. However, access and affordability of these drugs remain challenging in low middle-income countries, including India. To improve the access to meaningful treatment options, India’s health insurance scheme, AB-PMJAY, has linked the oncology packages to National Cancer Grid (NCG) resource-stratified guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
